NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 551-557

  Paniagua, Ramón ^a   Ventura, María De Jesús ^a   Ávila Díaz, Marcela ^a   Hinojosa Heredia, Héctor ^b   Méndez Durán, Antonio ^c   Cueto Manzano, Alfonso ^a   Cisneros, Alejandra ^d   Ramos, Alfonso ^e   Madonia Juseino, Clara ^e   Belio Caro, Francisco ^f   García Contreras, Fernando ^d   Trinidad Ramos, Pedro ^a   Vázquez, Rosario ^g   Ilabaca, Begoña ^h   Alcántara, Guadalupe ^a   Amato, Dante ⁱ  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Hospital General de Zona 47   (Mexico)

^c Hospital General Regional 25   (Mexico)

^d Hospital General de Zona No 76   (Mexico)

^e Hospital General Regional 2   (Mexico)

^f Hospital General Regional No 1 IMSS   (Mexico)

^g Hospital General de Zona 194   (Mexico)

^h Hospital General de Zona IMSS   (Mexico)

ⁱ UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Dialysis modality; End stage renal disease; Fluid overload; Mortality; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; FLUID BALANCE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HYPERVOLEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; EXTRACELLULAR FLUID; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 75649141269     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp395     Document Type: Article

References (40)

1. Greaves SC, Sharpe DN. Cardiovascular disease in patients with end-stage renal failure. Aust N Z J Med 1992; 22: 153-159
2. Huting J, Schutterle G. Cardiovascular factors influencing survival in end-stage renal disease treated by continuous ambulatory peritoneal dialysis. Am J Cardiol 1992; 69: 123-127
3. London GM, Marchais SJ, Metivier F et al. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant 2000; 15(Suppl 5): 97-104 (Pubitemid 30784398)
4. Gilbert RE, Connelly K, Kelly DJ et al. Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. Clin J Am Soc Nephrol 2006; 1: 193-208
5. Collins AJ, Hao W, Xia H et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-1074
6. Zethelius B, Berglund L, Sundstrom J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116
7. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-620
8. Haug C, Metzele A, Steffgen J et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994; 26: 246-249
9. Gangji AS, Helal BA, Churchill DN et al. Association between N-terminal propeptide B-type natriuretic peptide and markers of hyper-volemia. Perit Dial Int 2008; 28: 308-311
10. Enia G, Mallamaci F, Benedetto FA et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
11. Plum J, Ziyaie M, Kemmer FW et al. Intraindividual comparison of ANP, cGMP and plasma catecholamines between HD and CAPD. Adv Perit Dial 1990; 6: 211-219
12. Günal AI, Ilkay E, Kirciman E et al. Blood pressure control and left ventricular hypertrophy in long-term CAPD and hemodialysis patients: a cross-sectional study. Perit Dial Int 2003; 23: 563-567
13. Struijk DG. Volume status in CAPD and APD: does treatment modality matter and is more always better? Perit Dial Int 2007; 27: 641-644
14. Rodriguez-Carmona A, Pérez-Fontán M, Garca-Naveiro R et al. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44: 132-145
15. Hannan WJ, Cowen SJ, Plester CE et al.Comparisonofbio-impedance spectroscopy and multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci (Lond) 1995; 89: 651-658
16. Sun G, French CR, Martin GR et al. Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiome-tryfor assessmentofpercentage bodyfatina large, healthy population. Am J Clin Nutr 2005; 81: 74-78
17. Pearson TA, Mensah GA, Alexander RW et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
18. Paniagua R, Amato D, Vonesh E et al. for the Mexican Nephrology Collaborative Study Group. Predictive value of natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008; 3: 407-415
19. Horl WH. Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Investig Med 2005; 53: 366-370
20. Suresh M, Farrington K. Natriuretic peptides and the dialysis patient. Semin Dial 2005; 18: 409-419
21. Clerico A, Recchia FA, Passino C et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: phys-iological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17-H29
22. Apple FS, Murakami MM, Pearce LA et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-5294
23. Khan NA, Hemmelgarn BR, Tonelli M et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005; 112: 3088-3096
24. Schleiffer T, Nagel D, Franz H et al. Endothelin and atrial natriuretic peptide in non-insulin-dependent diabetic versus nondiabetic patients on chronic hemodialysis. Ren Fail 1994; 16: 747-758
25. Masson S, Latini R, Anand IS et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-1538
26. Omland T, Sabatine MS, Jablonski KA et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007; 50: 205-214
27. Khalifeh N, Haider D, HörlWH. Natriuretic peptidesinchronic kidney disease and during renal replacement therapy: an update. J Investig Med 2009; 57: 33-39
28. Biasioli S, Zamperetti M, Borin D et al. Significanceof plasma B-type natriuretic peptide in hemodialysis patients: blood sample timing and comorbidity burden. ASAIO J 2007; 53: 587-591
29. Paniagua R, Orihuela O, Ventura MJ et al. Echocardiographic, elec-trocardiographic and blood pressure changes induced by Icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int 2008; 73(Suppl 108): S125-S130
30. Sommerer C, Heckele S, Schwenger V et al. Cardiac biomarkers are influenced by dialysis characteristics. Clin Nephrol 2007; 68: 392-400
31. Dautin G, Boudjeltia S, Soltani Z et al. The changes in NT-proBNP plasma concentrations during dialysis are highly dependent of the dialysis membrane ultrafiltration coefficient. Clin Chim Acta 2007; 376: 237-239
32. Iwashima Y, Horio T, Takami Y et al. Effects of the creation of arte-riovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40: 974-982
33. Ortega O, Gallar P, Muñoz M et al. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract 2004; 97: c125-c130
34. Vonesh EF, Snyder JJ, Foley RN et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66: 2389-2401
35. Jaar BG, Coresh J, Plantinga LC et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 1430: 174-183
36. Ozkahya M, Ok E, Cirit M et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489-1493
37. Van Biesen W, Vanholder R, Verbeke F et al. Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? Perit Dial Inter 2006; 26: 429-434
38. Van Biesen W, Verbeke F, Devolder I et al. The relation between salt, volume, and hypertension: clinical evidence for forgotten but still valid basic physiology. Perit Dial Inter 2008; 28: 596-600
39. He FJ, MacGregor GA. Salt intake and cardiovascular disease. Nephrol Dial Transplant 2008; 23: 3382-3385
40. Fein P, Chattopadhyay J, Paluch MM et al. Enrollment fluid status is independently associated with long-term survival of peritoneal dialysis patients. Adv Perit Dial 2008; 24: 79-83